What is the 13F Pro Quality Score for ABEO?

13F Pro ranks ABEONA THERAPEUTICS INC. (ABEO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABEO's current score at https://13fpro.ai/research/ABEO (free sign-up required for the full ranking).

Where does 13F Pro source ABEO data?

All ABEONA THERAPEUTICS INC. fundamentals and ownership data come directly from SEC EDGAR. ABEONA THERAPEUTICS INC. files with the SEC under CIK 318306. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABEO in?

ABEONA THERAPEUTICS INC. (ABEO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ABEO research updated on 13F Pro?

ABEO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ABEONA THERAPEUTICS INC.(ABEO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 318306 ABEO stock profile & AI dashboard →

13F Pro Quality Score

44.3/100

Rank #1,778 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.0/100

Profitability

99.0/100

Balance Sheet

99.0/100

Earnings Quality

30.0/100

Free Cash Flow

2.1/100

Institutional Flow

24.8/100

Revenue Scale

3.2/100

Dilution Risk

1.9/100

ABEO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ABEONA THERAPEUTICS INC. (ABEO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABEO at 44.3/100 on a 32-signal composite quality model, placing it at rank #1,778 of 2,879 stocks — the bottom half of the AI-ranked universe. ABEO scores in the top quartile across profitability (99.0), balance sheet strength (99.0). Areas of concern include free cash flow (2.1) and revenue scale (3.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ABEONA THERAPEUTICS INC. reports quarterly revenue of $8.7M, net income of $-17.1M, free cash flow of $-20.7M. Top institutional holders of ABEO by reported 13-F value include Nantahala Capital Management,, BlackRock,, AIGH Capital Management, based on the most recent SEC filings. ABEO trades on the Nasdaq exchange and files with the SEC under CIK 318306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABEO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ABEONA THERAPEUTICS INC. directly from SEC EDGAR. ABEONA THERAPEUTICS INC.'s 13F Pro composite quality score has ranged between 4 and 44 since 2021, currently 44.3 — an improving long-term trajectory across 16 quarterly and live scoring snapshots.

✦

Fun facts about ABEONA THERAPEUTICS INC.

Quirks, history, and lore behind ABEO — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · focused on rare and life-threatening diseases · headquartered in the Philadelphia area.
2
The Numbers
A classic pre-revenue biotech with a small-cap market footprint — more money goes into the lab than comes out the other end, at least for now.
3
The History
Born out of research into cell and gene therapy, the company has spent years developing treatments aimed at genetic disorders that have few or no other options.
4
The Secret
Its pipeline targets conditions so rare that orphan drug designation from the FDA is basically a recurring theme — small patient populations, big unmet need.
5
The Lore
The company's name is borrowed from a Greek mythological figure — a deity associated with healing and restoration, which is on-the-nose for a gene therapy shop.
6
The Giveaway
Its lead programs have targeted recessive dystrophic epidermolysis bullosa — a severe skin disease — using gene-corrected cell therapies, making it one of the few companies tackling this brutal condition head-on.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$8.7M

Net Income

Q1 2026

$-17.1M

Free Cash Flow

Q1 2026

$-20.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$5.8MFY 2025

FY22 $1.4MFY23 $3.5MFY24 —FY25 $5.8M

Net Income

+211.7% YoY

$71.2MFY 2025

FY22 $-39.7MFY23 $-54.2MFY24 $-63.7MFY25 $71.2M

Operating Income

-39.3% YoY

$-89.4MFY 2025

FY22 $-50.9MFY23 $-47.1MFY24 $-64.2MFY25 $-89.4M

EPS (Diluted)

+165.2% YoY

$1.01FY 2025

FY22 $-5.53FY23 $-2.53FY24 $-1.55FY25 $1.01

Total Assets

+101.6% YoY

$219.6MFY 2025

FY22 $64.2MFY23 $64.0MFY24 $108.9MFY25 $219.6M

Total Debt

+29.6% YoY

$32.3MFY 2025

FY22 —FY23 —FY24 $24.9MFY25 $32.3M

Op. Cash Flow

-36.3% YoY

$-76.3MFY 2025

FY22 $-43.5MFY23 $-37.0MFY24 $-56.0MFY25 $-76.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$5.8M	—	$3.5M +147.5%	$1.4M -85.9%	$10.0M	—
Net Income	$71.2M +211.7%	$-63.7M -17.6%	$-54.2M -36.5%	$-39.7M +52.9%	$-84.2M -10.4%	$-76.3M
Operating Income	$-89.4M -39.3%	$-64.2M -36.2%	$-47.1M +7.4%	$-50.9M +37.5%	$-81.4M -5.6%	$-77.1M
EPS (Diluted)	$1.01 +165.2%	$-1.55 +38.7%	$-2.53 +54.2%	$-5.53	—	—
Total Assets	$219.6M +101.6%	$108.9M +70.2%	$64.0M -0.3%	$64.2M -57.5%	$151.2M -32.3%	$223.4M
Total Debt	$32.3M +29.6%	$24.9M	—	—	—	—
Operating Cash Flow	$-76.3M -36.3%	$-56.0M -51.4%	$-37.0M +14.9%	$-43.5M -24.2%	$-35.0M +44.3%	$-62.8M

Get alerted when ABEO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ABEONA THERAPEUTICS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABEO

Nantahala Capital Management, LLC
$22.5M5,013,052 sh
BlackRock, Inc.
$14.3M3,195,530 sh
AIGH Capital Management LLC
$13.9M3,100,000 sh
Cable Car Capital, LP
$13.5M3,007,329 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$12.0M2,676,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.7M2,164,851 sh
Propel Bio Management, LLC
$6.0M1,329,899 sh
KENNEDY CAPITAL MANAGEMENT LLC
$5.7M1,263,511 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.4M1,209,797 sh
GOLDMAN SACHS GROUP INC
$5.1M1,130,619 sh

Fund	Value	Shares
Nantahala Capital Management, LLC	$22.5M	5,013,052
BlackRock, Inc.	$14.3M	3,195,530
AIGH Capital Management LLC	$13.9M	3,100,000
Cable Car Capital, LP	$13.5M	3,007,329
SUVRETTA CAPITAL MANAGEMENT, LLC	$12.0M	2,676,000
VANGUARD CAPITAL MANAGEMENT LLC	$9.7M	2,164,851
Propel Bio Management, LLC	$6.0M	1,329,899
KENNEDY CAPITAL MANAGEMENT LLC	$5.7M	1,263,511
GEODE CAPITAL MANAGEMENT, LLC	$5.4M	1,209,797
GOLDMAN SACHS GROUP INC	$5.1M	1,130,619

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

ABT

ABBOTT LABORATORIES

Put ABEO on your watchlist

Track score changes the day ABEONA THERAPEUTICS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABEO a good stock to buy?

13F Pro's AI-powered analysis of ABEONA THERAPEUTICS INC. (ABEO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABEO are available on the ABEO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ABEO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABEO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ABEONA THERAPEUTICS INC.'s investment landscape.